In the interests of reducing spam, we have removed individual email addresses. If you would like to contact someone, please use email@example.com. Our general email address is firstname.lastname@example.org.
Dr Anne Dobrée - Head of Seed Funds
As Head of Seed Funds at Cambridge Enterprise, Anne has overseen strong growth in our investment activities, with Seed Funds investing over £5 million each year in young companies.
Highlights include the purchase of Cambridge CMOS Sensors by ams, and the sale of Quethera to Astellas Pharma. Anne has also served on many boards including those of Cambridge CMOS Sensors, Aqdot, Cambridge Touch Technologies, Psyomics, Morphogen-IX and Quethera. She was a founding member of Praxis Auril, which supports Knowledge Exchange Commercialisation in the UK.
Anne’s early career includes experience in technology transfer at Imperial College Innovations Limited, in pharmaceutical development at Evans Medical, and in pharmaceutical product training at Information Transfer.
Anne holds a BSc in Medical Microbiology and a PhD in Immunology.
Anne joined the technology transfer team at the University of Cambridge in 2001, and has been involved with Cambridge Enterprise since its foundation in 2006, including as Interim Director just prior to this. She joined the Seed Funds team in 2008 and was appointed Head of Seed Funds in 2011.
Dr Christine Martin - Deputy Head of Seed Funds
As Head of Life Science investment, Christine works to help create companies across the breadth of the life sciences, with a focus on drug discovery. She works with a broad portfolio, including University of Cambridge spin-outs Pharmenable, Spirea, Carrick Therapeutics, STORM Therapeutics, Z-factor, PhoreMost, Qkine and PolyProX.
Christine has extensive experience in all stages of the investment process including due diligence, deal negotiation and investment management. She currently sits on the board of five portfolio companies as well as being an observer for another three.
Previously, Christine worked for six years in the Cambridge Enterprise Life Sciences Technology Transfer team managing the licensing of University IP. Christine also managed the University of Cambridge-GSK open innovation drug discovery initiative based at the Stevenage Bioscience Catalyst, working closely with academics to gain funding to develop translational projects.
Prior to joining Cambridge Enterprise, Christine enjoyed 11 years working at Biotica, a University spin-out.
Christine has an MA and DPhil from the University of Oxford, has authored over 20 peer-reviewed journal articles and is an inventor on over 20 patents. She was the recipient of the Arthur E. Schwarting award in 2006 and featured in BioBeat’s 50 Movers and Shakers in BioBusiness 2018.
Christine joined Cambridge Enterprise in September 2011.
Dr Fatima Kranc - Senior Investment Associate (Life Sciences)
Fatima is a Senior Investment Associate in the Seed Funds team, whose focus is on early-stage life science spin-outs.
Fatima is a life sciences professional supporting academics at the University of Cambridge to develop technologies and build new companies to deliver socio-economic impact from research. With other Seed Fund team members, she works to help academics write business plans and build teams to successfully win pre-seed and seed investments.
Prior to joining Cambridge Enterprise, Fatima held a MRC Career Development Fellowship at the University of Oxford and went on to become a science translation ambassador. She has over 10 years’ experience in consultancy, technology transfer and management, having previously worked for Oxford University Innovation, Cancer Research Technology/CRUK and recently as commercialisation manager at the Babraham Institute in Cambridge.
Fatima holds a Biology degree from the University of Porto and a DPhil from the Medical Sciences division at the University of Oxford.
Fatima joined Cambridge Enterprise in March 2020.
Dr Elaine Loukes - Investment Director (Physical Sciences)
Elaine is an Investment Director in the Seed Funds team, focusing on spin-out opportunities emerging from the physical sciences.
Since joining Cambridge Enterprise, she has spun-out nine new companies and worked on several follow-on funding rounds. She has held many director positions and currently sits on the boards of PervasID, Intellegens, Sorex, Xampla and CB2Tech as well as being an observer of Audiotelligence and Riverlane.
She has extensive experience in all stages of the investment process including due diligence, financial modelling, deal negotiation and investment management.
Elaine has worked in early-stage tech investing since 2001. At Dresdner Kleinwort Capital, she sourced new investment opportunities and managed the direct-investment portfolio for early-stage tech deals as well as leading on a £2bn fund of funds secondary sale. At PUK Ventures she focused on early-stage tech opportunities emerging from the public sector and UK universities.
Elaine has a BSc in Laser Physics and Optoelectronics (University of Strathclyde), a PhD in Physics (Optoelectronics Research Centre, University of Southampton) and qualified as a Chartered Accountant (ICAEW) in 2000.
Elaine Joined Cambridge Enterprise in December 2015.
Dr Alisa Molotova - Investment Associate (Life Sciences)
Alisa is an Investment Associate in the Seed Funds team with a focus on spin-outs within the life sciences.
Prior to working at Cambridge Enterprise, Alisa lead the commercial strategy at a London-based start-up that had built a platform trusted by scientists at 900+ universities. She was also an executive for Global Biotech Revolution, a non-profit organisation with the primary mission to inspire and support the next generation of professionals in biotechnology. Alisa’s experience extends to working in biopharm innovation R&D and corporate innovation at leading pharmaceutical companies.
Alisa has recently completed a Wellcome Trust PhD programme in Stem Cell Biology & Medicine at the University of Cambridge and has graduated top of the class with MSci in Genetics at the University of Glasgow.
Alisa joined Cambridge Enterprise in September 2019.
Chris Gibbs - Investment Manager
Chris is an Investment Manager in the Seed Funds team focusing on spin-out opportunities emerging from the physical sciences.
Chris has spent over 15 years in UK high tech spin-outs and technology transfer. While Head of Engineering at CMR Fuel Cells in Cambridge, Chris led multi-disciplinary teams developing and delivering cleantech products to major multinational partners. He also co-founded Amalyst, a spin-out from University College London where, as Chief Technology Officer, he led its efforts in novel catalyst development for the energy transition. Chris joined UCL Business as a Senior Business Manager in 2016 where he helped commercialise a broad range of technologies from the physical sciences including the successful spin-out Bramble Energy.
Chris studied Chemical Engineering earning his BSc at the University of Tennessee with a magna cum laude distinction and his MSc from the University of South Carolina. He is passionate about the 21st century energy transition especially increasing hydrogen as an energy vector.
Chris joined Cambridge Enterprise in September 2020.
James Thomas - Senior Investment Associate (Software)
James is a Senior Investment Associate in the Seed Funds team, whose focus is on early-stage software spin-outs.
James works with teams both before and after they consider forming a company, assisting with the development of business plans and value propositions with a view to the team making applications and pitches for Pre-seed and Seed investments. James also attends the Board meetings of the University spin-out companies RoboK as a Director, and BKwai and Bond180 as an observer.
Prior to joining Cambridge Enterprise, James worked for a Cambridge-based software start-up for three years in a variety of internal and client-facing roles. Starting as an analyst delivering consultancy projects for clients, he progressed into account management while also contributing to sales, feature development and testing.
James has an MA in Natural Sciences from the University of Cambridge, studied Management at the Cambridge Judge Business School, and has an MBA from the Quantic School of Business and Technology.
James joined Cambridge Enterprise in October 2017
Helen Shaw - Data Coordinator
Helen ensures that data relating to Seed Funds projects and investments is captured and updated effectively.
Prior to joining Cambridge Enterprise, Helen worked as a Data Coordinator in the Paediatric Intensive Care Unit at Addenbrooke’s hospital.
Helen has an MSc in Information Systems Design from Kingston University and a BSc in Psychology from Northumbria University.
Helen joined Cambridge Enterprise in July 2019.
Vicky McDonnell - Seed Funds PA
Vicky job shares the role of PA to the Seed Funds team with Caroline Tann. Together they provide seamless PA and administrative support to the team.
Vicky is also a member of the company-wide Professional Assistants Team which provides a high level of personal, efficient and confidential admin support to Cambridge Enterprise.
Vicky is very involved with the organisation of the monthly Investment Committee meetings. She also assisted with the formation of the Professional Assistants Team and remains involved in the continuing development of this team.
Before joining Cambridge Enterprise, Vicky previously worked for the Physics Department in the University of Cambridge where she acted as PA to three senior staff and administrative support for the rest of the group. Prior to this, she was a PA to the Director of a regional building contractor and PA/Administrator to a computer consultancy firm.
Vicky holds an NVQ In Business Administration which she completed with a distinction.
Vicky joined Cambridge Enterprise in March 2017.
Image: Pound coins, courtesy Creative Commons.